A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02326454 |
Recruitment Status :
Completed
First Posted : December 29, 2014
Last Update Posted : August 8, 2018
|
Sponsor:
Light Sciences Oncology
Collaborator:
Mundipharma Research Limited
Information provided by (Responsible Party):
Light Sciences Oncology
- Study Details
- Tabular View
- Results Submitted
- FDAAA 801 Violations
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | March 29, 2017 |
Actual Study Completion Date : | March 29, 2017 |
Certification/Extension First Submitted : | April 19, 2018 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 |
August 2, 2023 | August 9, 2023 |